SCHEMBL160105

SCHEMBL160105

NS(=O)(=O)c1nc2ccc(O)cc2s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 19/20 1.00
CA1 P00915 10/20 1.00
CA4 P22748 5/20 1.00
CA12 O43570 4/20 1.00
CA5A P35218 3/20 1.00
CA14 Q9ULX7 3/20 1.00
CA9 Q16790 3/20 1.00
CA6 P23280 2/20 1.00
CA5B Q9Y2D0 2/20 1.00
CA7 P43166 3/20 0.60
KDM4E B2RXH2 1/20 0.57
LMNA P02545 1/20 0.57
CA3 P07451 1/20 0.57
PKM P14618 1/20 0.57
KMT2A Q03164 1/20 0.57
HIF1A Q16665 1/20 0.57
CA13 Q8N1Q1 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
GAA P10253 1/20 0.57
HTT P42858 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10924391 0.94 CA2 (0.88) CA2CA1CA4CA12CA5A
SCHEMBL564235 0.87 CA2 (1.00) CA2CA1CA4CA12CA5A
SCHEMBL5174764 0.83 CA2 (0.91) CA2CA1CA4CA12CA5A
SCHEMBL9459715 0.81 CA2 (1.00) CA2CA1CA4CA12CA5A
SCHEMBL10473056 0.80 CA2 (0.69) CA2CA1CA4CA12CA5A
SCHEMBL2616102 0.80 CA2 (0.69) CA2CA1CA4CA12CA5A
SCHEMBL10474766 0.80 CA2 (0.69) CA2CA1CA4CA12CA5A
SCHEMBL10473137 0.80 CA2 (0.69) CA2CA1CA4CA12CA5A
SCHEMBL10473058 0.80 CA2 (0.68) CA2CA1CA4CA12CA5A
SCHEMBL11118371 0.77 CA2 (0.80) CA2CA1CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 673 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023059810-A1 STENTS AND METHODS OF USE UNIVERSITY OF CONNECTICUT (US) 2023-04-13 WO claimed
WO-2023044463-A1 SILK FIBROIN DERIVED BRUSH-LIKE POLYMERS UNIVERSITY OF CONNECTICUT (US) 2023-03-23 WO claimed
EP-1526869-A1 COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CARBONIC ANHYDRASE INHIBITOR FOR THE TREATMENT OF NEOPLASIA Pharmacia Corporation (US) 2005-05-04 EP claimed
US-20040067992-A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia PHARMACIA CORPORATION 2004-04-08 US claimed
WO-2004014430-A1 COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CARBONIC ANHYDRASE INHIBITOR FOR THE TREATMENT OF NEOPLASIA PHARMACIA CORPORATION (US) 2004-02-19 WO claimed
US-6313155-B1 Composition and method for treating macular disorders BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2001-11-06 US claimed
EP-0126684-B1 DRUG DELIVERY SYSTEM UTILIZING THERMOSETTING GELS MERCK & CO. INC. (US) 1991-08-28 EP claimed
EP-0079269-B1 HYDROXY-SUBSTITUTED-2-BENZOTHIAZOLESULFONAMIDE FOR THE TOPICAL TREATMENT OF ELEVATED INTRAOCULAR PRESSURE MERCK & CO. INC. (US) 1986-05-14 EP claimed
EP-0126684-A2 Drug delivery system utilizing thermosetting gels MERCK & CO. INC. (US) 1984-11-28 EP claimed
US-4474751-A SUSTAINED RELEASE USING AN ALKYLENEDIAMINE-MODIFIED ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER MERCK & CO., INC. (US) 1984-10-02 US claimed
US-4386098-A CARBONIC ANHYDRASE INHIBITOR MERCK & CO., INC. (US) 1983-05-31 US claimed
EP-0079269-A1 Hydroxy-substituted-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure MERCK & CO. INC. (US) 1983-05-18 EP claimed
EP-3129065-B1 TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS AKAMARA THERAPEUTICS INC (US) 2026-05-13 EP disclosed
US-20260124324-A1 PHOTOCLICK CHEMISTRY OF SILK FOR TEMPORARY UV TATTOOS TUFTS COLLEGE (US) 2026-05-07 US disclosed
EP-4734896-A2 BIOPOLYMER-BASED TYMPANOSTOMY TUBES WITH PROGRAMMABLE, TUNABLE, AND ON-DEMAND DEGRADATION Trustees Of Tufts College (US) 2026-05-06 EP disclosed
EP-4735018-A2 CENTRIFUGALLY-MOLDED ARTICLES AND METHODS Trustees Of Tufts College (US) 2026-05-06 EP disclosed
US-4386098-A CARBONIC ANHYDRASE INHIBITOR MERCK & CO., INC. (US) 1983-05-31 US disclosed
EP-0079269-A1 Hydroxy-substituted-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure MERCK & CO. INC. (US) 1983-05-18 EP disclosed
EP-0070239-A1 Benzothiazolesulfonamide derivatives, their preparation and ophthalmic compositions containing said derivatives MERCK & CO. INC. (US) 1983-01-19 EP disclosed
EP-0070239-A1 Benzothiazolesulfonamide derivatives, their preparation and ophthalmic compositions containing said derivatives MERCK & CO. INC. (US) 1983-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067992-A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia CA2, CA1, CA4 CA2 1/4885CA1 2/4885CA4 3/4885
US-20260124324-A1 PHOTOCLICK CHEMISTRY OF SILK FOR TEMPORARY UV TATTOOS PTMS, ITK, MATK CA2 4601/4885CA1 4842/4885CA4 4312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.